BiotechPark with Innovation- and Incubationscenter

Berlin-Buch, with its long tradition of excellent biomedical basic and clinical research as well as clinical expertise, is an ideal environment for life science companies. The campus atmosphere is conducive to scientific exchange, technology transfer and collaborative projects.
With an area of approximately 45,000 m², the BiotechPark Berlin-Buch is one of the largest biotech parks in Germany. Here entrepreneurs and companies find affordable, industry-specific laboratory and office space with state-of-the-art facilities. Start-ups can grow and thrive in the Innovation and Incubation Center, building areas on the Campus allow for future development. The managing company, Campus Berlin-Buch GmbH, supports the companies in all matters and provides comprehensive service.
Currently, 75 companies are located on campus and employ around 850 people. More than fifty of these companies are in the biotech sector, several others offer services for the life science industry. Since 1998 the number of employees of the biotech companies has more than doubled.
The business fields of the companies range from medical technology products, molecular biological diagnostics and treatments, preclinical pharmacological and pharmacogenomic tests, RNA technologies, the search for pharma-relevant target molecules, production and testing of drugs and the analysis and synthesis of biomolecules.
From 2023 the new BerlinBioCube start-up center in BiotechPark Berlin-Buch will offer an additional 8,000 square meters of laboratory and office space and attractive services for start-ups in the fields of biotechnology and medical technology as well as adjacent areas.
„Made in Buch“ stands for high quality and innovation in the life sciences. Selected products can be found here.

News innovation
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contrac...
more ...Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796.
more ...Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row.
more ...Events Campus
09.09.2025, 09:00
From Target to Market - The BBA Biotech & Pharma Summer School
The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.
more ...14.09.2025, 11:00
Tag des offenen Denkmals - Einladung auf den Wissenschaftscampus Berlin-Buch
Offenes Wissenschaftsmuseum und Führung zur Geschichte des Campus Berlin-Buch
more ...18.09.2025, 17:00
Talk im Cube: IP Strategies in Biotechnology
We are excited to continue the Talks in the Cube with a further expert discussion focused on Strategies for Intellectual Property Rights in Biotechnology.
more ...